InMed Sets 1-for-10 Share Consolidation Ahead of November 4 Mentari Merger Vote
INM has more than doubled off its 52-week low of $0.575 on elevated volume (2.0× avg).
Summary
InMed will consolidate its shares 1-for-10, cutting the count from 5,493,735 to about 549,374, contingent on shareholders approving the Mentari merger proposals at the November 4 meeting. Post-split trading begins November 5 under a new CUSIP.
Key Events · M&A and Partnerships · INM
-
1-for-10 Consolidation Announced
InMed will consolidate all issued and outstanding Common Shares at one post-consolidation share for each ten pre-consolidation shares, reducing the count from 5,493,735 to approximately 549,374 on a non-diluted basis.
-
Conditional on November 4 Vote
The consolidation only proceeds if shareholders approve Proposal No. 1 (Nasdaq Share Issuance), Proposal No. 2 (Return of Capital) and Proposal No. 3 (Redomestication) at the November 4, 2026 annual general and special meeting.
-
Trading Timeline and New Identifiers
Completion is expected after market close on November 4, 2026, with consolidation-adjusted trading on Nasdaq beginning at market open November 5, 2026 under new CUSIP 457637809 and ISIN CA4576378091.
-
No Economic Change to Holders
Each shareholder holds the same percentage of outstanding shares immediately after the consolidation; option and warrant exercise prices and share counts are adjusted proportionately, and fractional shares are rounded with no cash paid.
Analysis · INM · Life Sciences
The mechanical fix for Nasdaq's $1 minimum bid requirement arrives immediately after the November 4 shareholder meeting: InMed will collapse its share count tenfold, from 5,493,735 to roughly 549,374 shares, but only if holders approve the Nasdaq share issuance, return of capital and redomestication proposals tied to the Mentari reverse merger. Economically, the consolidation changes nothing for holders, who retain the same percentage ownership while options and warrants are adjusted proportionately; what it does is lift the per-share price roughly tenfold. The real event is the November 4 vote, since existing InMed holders are set to own just 1.01% of the combined company, meaning approval effectively hands the company to Mentari. Should the proposals fail, neither the consolidation nor the merger proceeds.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INM was trading at $1.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9M. The 52-week trading range was $0.58 to $2.33. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.